UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-Q(Mark One)[x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31, 2009OR[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number ______________ PURE PHARMACEUTICALS CORPORATION(Exact name of Registrant as Specified in Its Charter)20549

FORM 10-Q

(Mark One)

[x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2010

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________to ___________________

Commission file number _______________

PURE PHARMACEUTICALS CORPORATION
(Exact name of Registrant as Specified in Its Charter)

NEVADA	45-0476087
(State or Other Jurisdiction of Incorporation or	(IRS Employer Identification No.)
Organization)


P.O. BOX 55, 1594 STONE MILL PARK,
BELLONA, NY	14415
(Address of Principal Executive Offices)	(Zip Code)

(315) 849-2822
(Registrant’s Telephone Number, Including Area Code)

~~________________~~_______________________________ (Former Name, Former Address and Former Fiscal Year, if ~~Changed~~ Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed ~~all~~ all reports required to be filed by Section 13 or 15(d) of the Securities ~~Exchange~~ Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes [x] No [ ]

Yes [x] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the exchange Act. (Check One)

Large Accelerated Filer [ ]

Accelerated Filer [ ]

Non-Accelerated Filer [ ]

Indicate by check mark whether the registrant is a shell ~~company~~ company (as defined in Rule 12b-2 of the Exchange Act).Yes [x] No [ ]

Yes [x] No [ ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.Yes [ ] No [ ]

Yes [ ] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

*Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [x]
(Do not check if a smaller reporting company)

PART ~~1FINANCIAL~~ 1 FINANCIAL INFORMATION

Item 1. Financial Statements.

PURE PHARMACEUTICAL CORPORATION
(A Development Stage Company)

FINANCIAL ~~STATEMENTSDECEMBER~~ ~~31, 2009~~STATEMENTS

MARCH 31, 2010

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)

	December 31,		September 30,
	March 31,		September 30,
	2009		2009
	2010		2009
	- $ -		- $ -
ASSETS
Current
Cash	626,~~510~~556		8,573
	6,510		8,573
	26,556		8,573
LIABILITIES
Current
Accounts payable and accrued liabilities	2439,~~507~~444		30,771
Long-term loans	43,431		59,314
Long-term loans (Note 2)	-		59,314
	67,938		90,085
	39,444		90,085
STOCKHOLDERS’ DEFICIT
Common Stock (Note 2)
Common Stock (Note 3)
Authorized: 100,000,000 common shares with a par value of $0.001 Issued and Outstanding: 12,600,000 common shares (September 30, 2009– 12,600,000)	12,600		12,600
Authorized: 100,000,000 common shares with a par value of $0.001
Additional paid up capital	223,800		191,400
Issued and Outstanding: 12,600,000 common shares (September 30, 2009 – 12,600,000)	12,600		12,600
Accumulated other comprehensive income	2,439		2,439
Additional paid in capital	292,200		191,400
Deficit accumulated during the development stage	(300,267	)	(287,951	)
Accumulated comprehensive loss	2,439		2,439
	(61,428	)	(81,512	)
Deficit accumulated during the development stage	(320,127	)	(287,951	)
	6,510		8,573
	(12,888	)	(81,512	)
	26,556		8,573

– See Accompanying Notes –

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

					~~Cumulative~~				Cumulative
					from
					Six months		Six months		from September
					September 24,
	Three months		Three months		ended		ended		24, 2004
	Three months		Three months		2004
	ended March		ended March		March 31,		March 31,		(Inception) to
	ended		ended		(Inception) to
	31, 2010		31, 2009		2010		2009		March 31, 2010
	December 31,		December 31,		December 31,
	- $ -		- $ -		- $ -		- $ -		- $ -
	2009		2008		2009
Revenue	-		4,310		-		8,310		20,398
	- $ -		- $ -		- $ -
Cost of sales	-		-		-		-		9,670
Revenue	-		4,000		20,398
	-		4,310		-		8,310		10,728
Cost of sales	-		-		9,670
Expenses
	-		4,000		10,728
Financing fees	-		-		-		-		5,600
Expenses
General and administrative	18,585		9,446		30,101		14,789		314,126
Financing fees	-		-		5,600
Interest on long-term loans	1,275		2,000		2,075		2,800		5,999
General and administrative	11,516		5,343		295,541
Write-down of inventory	-		-		-		-		5,130
Interest on long-term loans	800		800		4,724
Net loss	(19,860	)	(7,136	)	(32,176	)	(9,279	)	(320,127	)
Write-down of inventory	-		-		5,130
Loss per share – basic and diluted	(0.00	)	(0.00	)	(0.00	)	(0.00	)
Net loss	(12,316	)	(2,143	)	(300,267	)
Weighted average number of common shares outstanding – basic and diluted	12,600,000		12,600,000		12,600,000		12,600,000
Loss per share – basic and diluted	(0.00	)	(0.00	)
Weighted average number of common shares outstanding- basic and dilutive	12,600,000		12,600,000

– See Accompanying Notes –

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

	Three		Three		Cumulative from
			Six months		Cumulative from
	months		months		September 24, 2004
	Six months		ended		September 24,
	ended		~~ended~~March 31,		2004(Inception) to
	December		December		December 31,
	March 31, 2010		2009		to March 31, 2010
	31, 2009		31, 2008		2009
	- $ -		- $ -		- $ -
Cash Flows From Operating Activities
Net loss	(1232,~~316~~176	)	(29,~~143~~279	)	(~~300~~320,~~267~~127	)
Non-cash items:
Accrued interest on long term loan	800		800		4,724
Donated capital	4,800		4,800		52,800
Donated capital	2,400		2,400		50,400
Accrued interest on long term loan	2,075		2,800		5,999
Write down of inventory	-		-		5,130
Write-down of inventory	-		-		5,130
Change in non-cash working capital items:
Change in non-cash working capital items
Inventory	-		-		(5,.130	)
Accounts payable and accrued liabilities	(68,~~264~~673	)	(~~263~~27,479	)	5439,~~507~~444
Net cash used in operating activities	15,380		794		(190,636	)
Net cash used in operations	(16,628	)	(29,158	)	(221,884	)
Cash Flows From Financing Activities
Proceeds from (repayment of) long-term loans	(1661,~~683~~389	)	-14,224		38(5,~~707~~999	)
Donated capital	3096,000		-		50116,000
Capital stock issued for cash	-		-		136,000
Net cash provided by financing activities	~~(13~~34,~~317~~611	)	-14,224		~~224~~246,~~707~~001
Effect of exchange rate changes	-		~~(29~~3,334	)	2,439
Increase (Decrease) In Cash	(217,~~063~~983	)	(~~765~~11,600	)	626,~~510~~556
Cash, beginning	8,573		12,459		-
Cash, ending	626,~~510~~556		~~13,224~~859		626,~~510~~556
Supplementary Cash Flow Information:
Cash paid for:
Interest	-5,999		-		-5,999
Income taxes	-		-		-

- See Accompanying Notes -

PURE PHARMACEUTICAL CORPORATION (A Development Stage Company) ~~NOTE TO THE FINANCIAL STATEMENTS DECEMBER 31, 2009 (Unaudited)~~

1.	BASIS OF PRESENTATION
	Unaudited Interim Consolidated Financial Statements
	The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. They may not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended September 30, 2009, included in the Company’s Form 10-K filed with the Securities and Exchange Commission. The unaudited interim financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended December, 31, 2009 are not necessarily indicative of the results that may be expected for the year ending September 30, 2010.
	We evaluated events occurring between the end of our fiscal quarter December 31, 2009 and February 12, 2010 when the financial statements were issued.
2.	COMMON STOCK
	During the three months ended December 31, 2009, the Company received $30,000 as the second installment of the $50,000 non-refundable required by the Letter of Intent (“LOI) entered into by the Company with 7167415 Canada Inc. on July 21, 2009. The LOI expired on July 23, 2009 and a definitive agreement was not entered into. Accordingly, the non-refundable deposit has been recorded as donated capital.

NOTES TO THE FINANCIAL STATEMENTS

~~Item~~MARCH 2.31, ~~Management's~~2010 ~~Discussion and Analysis of Financial Condition and Results of Operations.~~(Unaudited)

~~Forward~~1. ~~Looking~~BASIS OF PRESENTATION Unaudited Interim Consolidated Financial Statements The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. They may not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended September 30, 2009, included in the Company’s Form 10-K filed with the Securities and Exchange Commission. The unaudited interim financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended March 31, 2010 are not necessarily indicative of the results that may be expected for the year ending September 30, 2010. In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders’ equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Examples include: estimates of loss contingencies, product warranties, product life cycles, product returns, and stock-based compensation forfeiture rates. Actual results and outcomes may differ from management’s estimates and assumptions. 2. LONG-TERM LOANS During the six months ended March 31, 2010, the Company fully repaid the long term loans in the amount of $61,389 including accrued interest of $5,999. 3. COMMON STOCK During the six months ended March 31, 2010, the Company received $30,000 as the second installment of a $50,000 non-refundable deposit under the terms of a Letter of Intent (“LOI”) entered into with 7167415 Canada Inc. on July 21, 2009. The LOI expired on July 23, 2009 and a definitive agreement was not completed. Accordingly, the non-refundable deposit was recorded as additional paid in capital. During the six months ended March 31, 2010, the Company received $66,000 from 7167415 Canada Inc. to repay long-term loan and to fund operating expenses. These funds were donated to the Company and it has no obligation to repay these funds. Accordingly, the $66,000 was recorded as additional paid in capital.

InItem ~~addition to historical information, the following discussion and other parts of this document may contain forward-looking statements~~2. ~~These statements~~Management's ~~relate~~Discussion to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms or other comparable terminology. These statements are only predictions. The events described in forward looking statements we make in this Form 10-Q may not occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you that these statements are not guarantees of future performance or events and ~~are~~Analysis ~~subject to a number~~ of ~~uncertainties~~ ~~risks~~Financial ~~and~~Condition ~~other influences, many of which are beyond our control that may influence the accuracy of the statements~~ and ~~the~~Results ~~projections upon which the statements are based. Moreover, neither we nor any other person assume responsibility for the accuracy and completeness~~ of ~~the forward-looking statements~~Operations. Except as may be required by law, we undertake no obligation to publicly update any of the forward-looking statements after the date of this report to conform such statements to actual results or to changes in our expectations.

~~Actual~~Forward ~~results~~Looking could differ materially from those anticipated by such forward-looking statements. The following discussion should be read in conjunction with the financial statements as well as other financial information appearing elsewhere in this document. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business.Statements

~~Our~~In ~~Business~~addition to historical information, the following discussion and other parts of this document may contain forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms or other comparable terminology. These statements are only predictions. The events described in forward looking statements we make in this Form 10-Q may not occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties risks and other influences, many of which are beyond our control that may influence the accuracy of the statements and the projections upon which the statements are based. Moreover, neither we nor any other person assume responsibility for the accuracy and completeness of the forward-looking statements. Except as may be required by law, we undertake no obligation to publicly update any of the forward-looking statements after the date of this report to conform such statements to actual results or to changes in our expectations.

~~The~~Actual ~~Company~~results ~~was~~could ~~formed~~differ inmaterially ~~order~~from tothose ~~seek business opportunities~~anticipated inby ~~the~~such ~~area~~forward-looking ~~of expertise of the Company's principal stockholder, Mr~~statements. ~~Roger Gordon,~~The ~~being~~following ~~biological~~discussion ~~and/or~~should ~~medical~~be ~~products~~read ~~for animal use. The Company~~in ~~principally~~conjunction ~~operated~~with in the ~~field~~financial ofstatements ~~generic~~as ~~animal~~well ~~health~~as ~~and~~other ~~nutrition products,~~financial ~~specifically medicated feed additives (MFAs). MFAs are used~~information ~~preventively~~appearing ~~and~~elsewhere ~~therapeutically~~ in ~~animal~~this ~~feed to prevent disease and foster growth in livestock~~document. InReaders ~~North~~are ~~America,~~also ~~90%~~urged ~~of all feed~~ to ~~animals~~carefully ~~contain MFAs,~~review ~~but~~and ~~has~~consider ~~been on~~ the ~~decrease~~various indisclosures ~~the~~made ~~last~~by ~~five~~us ~~years.~~which ~~Our~~attempt ~~intended~~to ~~customers~~advise ~~operate~~interested inparties ~~the~~of poultry, swine and cattle markets. The Company has historically focused its efforts on generic MFAs, as they have come off patent, therefore making them more economical to register with requisite regulators in the ~~United States~~factors ~~and~~which ~~Canada,~~affect ~~with~~our ~~a view to bringing the products to market~~business.

~~The~~Our Company ceased to market an under licensed related-party owned MFA, Oxytetracycline, and is continuing its discussions with third parties in connection with a possible merger agreement or share exchange pursuant to which control of the Company may be sold to such third parties. As market dynamics have undergone significant systemic changes over the past four years with the emergence of avian flu and the attendant fall in poultry consumption worldwide, management realized the identification process for new MFAs cannot be done with the limited resources of the Company. Furthermore, with the prices of feed, particularly maize, at record high prices, out intended customers have been hesitant to add to their expenses.Business

The Company's ~~activities~~was toformed ~~date~~in ~~have~~order ~~been~~to ~~primarily organizational~~seek business opportunities in ~~nature~~the ~~and~~area asof aexpertise ~~result~~of the Company's ~~must~~principal bestockholder, ~~considered~~Mr. toRoger Gordon, bebeing ~~in its~~biological ~~developmental~~and/or ~~stage~~medical products for animal use. The Company principally ~~relies~~operated ~~solely~~in on the ~~efforts~~field of ~~its~~generic animal health and nutrition ~~management~~products, specifically medicated feed additives (MFAs). MFAs are used preventively and ~~director~~therapeutically in animal feed to prevent disease and ~~has~~foster growth noin ~~employees~~livestock. In North America, ~~owns~~90% ~~few~~of ~~business~~all ~~assets~~feed to animals contain MFAs, ~~technology~~but orhas ~~real~~been ~~estate~~on the decrease in the last five years. Our intended customers operate in the poultry, swine and ~~since~~cattle ~~inception~~markets. The Company has ~~been~~historically focused ~~primarily~~its ~~involved~~efforts on generic MFAs, as they have come off patent, therefore making them more economical to register with requisite regulators in the United ~~developing~~States and ~~refining~~Canada, ~~its~~with ~~business~~a ~~plan,~~view ~~preliminarily~~to bringing the products to market.

~~identifying~~The ~~generic~~Company ~~MFAs~~ceased ~~for~~to ~~registration,~~market ~~raising~~an ~~initial~~under licensed related-party ~~capital~~owned MFA, Oxytetracycline, and ~~looking~~is continuing its discussions with third parties in connection with a possible merger agreement or share exchange pursuant to which control of the Company may be sold to such third parties. As market dynamics have undergone significant systemic changes over the past four years with the emergence of avian flu and the attendant fall in poultry consumption worldwide, management realized the identification process for ~~other~~new ~~potential~~MFAs ~~shareholder~~cannot ~~maximizing~~be done ~~corporate~~with the limited resources of the Company. Furthermore, with the prices of ~~actions~~feed, particularly maize, at record high prices, out intended customers have been hesitant to add to their expenses.

~~Management~~The ~~previously~~Company's ~~determined~~activities to ~~refocus,~~date ~~assess~~have ~~and~~been primarily ~~identify~~organizational ~~alternative~~in ~~business~~nature ~~strategies~~and ~~due~~as a result the Company must be considered to ~~prolonged~~be ~~high~~in its ~~prices~~developmental stage. The Company relies solely on the efforts of ~~maize~~its management and ~~other~~director ~~inputs~~and has no employees, owns few business assets, technology or real estate and ~~other~~since ~~general~~inception ~~systemic~~has ~~economic~~been ~~conditions~~primarily ~~affecting~~involved ~~the~~in developing and refining its business ofplan, ~~the~~preliminarily ~~Company~~identifying generic MFAs for registration, raising initial capital, and looking for other potential shareholder maximizing corporate actions.

~~Recent~~Management ~~Developments~~previously determined to refocus, assess and identify alternative business strategies due to prolonged high prices of maize and other inputs and other general systemic economic conditions affecting the business of the Company.

~~The~~Recent Company has booked no sales for this period and had received $30,000 donated capital from an outside third party during the period. As a result of the prolonged high prices of inputs and other general conditions affecting the business of the Company, management determined, earlier in its fiscal year, to refocus, assess and identify alternative business strategies. In July 2008, the Company was quoted on the OTC Bulletin Board under the symbol “PPMA”. The Company is continuing its discussions with third parties in connection with a possible merger or share exchange pursuant to which control of the Company may be sold to such third parties.Developments

~~Results~~The Company has booked no sales for this period and had received $66,000 donated capital from an outside third party during the period. As a result of ~~Operations~~the prolonged high prices of inputs and other general conditions affecting the business of the Company, management determined, earlier in its fiscal year, to refocus, assess and identify alternative business strategies. In July 2008, the Company was quoted on the OTC Bulletin Board under the symbol “PPMA”. The Company is continuing its discussions with third parties in connection with a possible merger or share exchange pursuant to which control of the Company may be sold to such third parties.

Results of Operations ~~for the Period ended December 31, 2009~~

~~The~~Results ~~Company did not earn any revenues in the previous 3 months ended December 31, 2009. We incurred operating expenses in the amount~~ of ~~$12,316~~ ~~for~~Operations ~~the three months ended December 31, 2009. Our net loss~~ for ~~the~~ ~~three months ended was $12,316 as compared to net loss of $2,143 for~~ the ~~three~~ ~~months~~Periods ended ~~December~~March 31, ~~2008. As at December 31, 2009 we had cash of~~ ~~$6,510. The Company’s losses stem from the payment of professional fees.~~ 2010

The Company ~~ceased~~did ~~its~~not ~~sales~~earn ~~and~~any ~~marketing~~revenues ofin the ~~Company’s Oxytetracyline~~three asmonths ~~well as the process of the Company pursuing opportunities in~~ended ~~the~~March ~~generic~~31, ~~MFAs areas~~2010. AsWe ~~stated~~incurred ingeneral ~~the~~and ~~prior~~administrative ~~quarter,~~expenses ~~the~~in ~~Company will not be importing further Oxytetracyline from~~ the ~~People’s~~amount ~~Republic~~ of ~~China which is~~ ~~idleling~~$18,585 ~~production until the overall economic situation improves;~~ and ~~our factory~~interest ~~suppliers~~on ~~have~~long-term ~~remained~~loans ~~dormant and have not provided an ETA as to when production would resume. Due to acute fluctuations in the price~~ of ~~key ingredients;~~$1,275 ~~corn~~for ~~and soybeans;~~ the ~~ability~~three ~~for~~months ~~producers to manage price~~ended ~~pressure~~March is31, ~~severely challenged~~2010. ~~Corn~~Our ~~prices~~net ~~see-sawed~~loss ~~and~~for ~~surged 3 to-5 fold in~~ the ~~last~~three 24 months toended ~~$750~~March ~~USD per bushel mid 2008. Since its high~~31, ~~the~~2010 ~~price~~was ~~has~~$19,860 ~~continued its volatility and~~ as ancompared ~~example from June 1st~~ to ~~December~~ ~~31th~~net ~~2009~~loss ~~prices~~of ~~swung 22% in 30 days from~~ $~~425~~7,136 ~~USD~~for ~~per bushel to $350 USD per bushel. Farmers and buyers are taking a wait and see approach and farmers in particular are not selling their crops and trying to time~~ the ~~market.~~three ~~Management~~months ~~and~~ended ~~analysts~~March ~~believe the competition for corn~~31, ~~once~~ ~~viewed as a commodity and now viewed as a matter of national security for countries, is here to stay~~2009. ~~Though~~As ~~prices~~at ~~have~~March ~~dropped in the first six months of 2009~~31, ~~the~~2010 ~~price~~we ishad ~~still~~cash ~~double that~~ of ~~three years ago in January 2006~~$26,556. ~~and have trended upwards in the last half of 2009~~ The ~~use~~Company’s oflosses ~~corn for the production~~stem offrom ~~ethanol and~~ the ~~agricultural~~payment ~~polices~~ of ~~leading~~professional ~~petroleum usage countries continue to exert price and demand pressures on the market1~~fees. ~~Also confounding the problem is worldwide health concerns and reaction to animal borne disease transmission to humans.~~

~~Due~~During to the ~~prolonged~~six ~~uncertainty~~months ~~and~~ended ~~relative~~March ~~high~~31, ~~historic prices~~2010, ofthe ~~inputs,~~Company incurred ~~this~~general ~~upward~~and ~~cycle~~administrative ~~has~~expenses ~~lasted~~in ~~for~~the 3amount ~~years~~of $30,101 and interest ~~general~~on ~~economic conditions~~long-term ~~which~~loans ~~are~~of ~~effecting~~$2,075. ~~the~~Our ~~business~~net ofloss for the ~~company;~~six ~~management~~months ~~has~~ended ~~determined~~March to31, ~~refocus~~2010 was $32,176 ~~assess~~compared to net loss of $9,279 ~~and~~for ~~identify~~the ~~alternative~~six ~~business~~months ended ~~strategies~~March 31, 2010.

1The ~~http://www~~Company ceased its sales and marketing of the Company’s Oxytetracyline as well as the process of the Company pursuing opportunities in the generic MFAs areas.~~financialpost~~ As stated in the prior quarter, the Company will not be importing further Oxytetracyline from the People’s Republic of China which is idleling production until the overall economic situation improves; and our factory suppliers have remained dormant and have not provided an ETA as to when production would resume.~~com/story~~ Due to acute fluctuations in the price of key ingredients; corn and soybeans; the ability for producers to manage price pressure is severely challenged.~~html?id=311350~~ Corn prices see-sawed and surged 3 to-5 fold in the last 24 months to $750 USD per bushel mid 2008. Since its high, the price has continued its volatility and as an example from Jan 1st to March 31th 2010 prices swung 28% in 30 days from $450 USD per bushel to $350 USD per bushel. Farmers and buyers are taking a wait and see approach and farmers in particular are not selling their crops and trying to time the market. Management and analysts believe the competition for corn, once viewed as a commodity and now viewed as a matter of national security for countries, is here to stay. Though prices have dropped from historic highs, the price is still double that of three years ago in January 2006, and have trended upwards in the first half of 2010 The use of corn for the production of ethanol and the agricultural polices of leading petroleum usage countries continue to exert price and demand pressures on the market1. Also confounding the problem is worldwide health concerns and reaction to animal borne disease transmission to humans.

~~Liquidity and Capital Resources~~ ________________________________________________1 http://www.financialpost.com/story.html?id=311350

~~Our~~Due ~~cash~~to ~~reserves~~the ofprolonged ~~$6,510~~uncertainty asand atrelative ~~December~~high ~~31, 2009~~historic ~~($8,573~~prices asof ~~at September 30~~inputs, ~~2009) are not sufficient to meet our funding needs beyond the next nine-month period. To~~ this ~~effect,~~upward ~~the~~cycle ~~Company~~has ~~will~~lasted ~~need to seek additional funding in the near future. We currently do not have a specific plan~~ for ~~obtaining~~3 ~~such funding~~years, ~~however,~~and wegeneral ~~anticipate that any additional funding~~economic ~~will~~conditions bewhich inare effecting the ~~form~~business of ~~equity financing from~~ the ~~sale~~company; ofmanagement ~~our common stock and/or~~has ~~loans~~determined ~~(interest or convertible). We currently do not have any arrangements in place for any future equity financing. We may also seek~~ to ~~obtain~~refocus, ~~short-term loans from our directors~~assess, ~~although~~and noidentify ~~such~~alternative ~~arrangements~~business ~~have as yet been made~~strategies. ~~There can be no assurance that we will be able to raise sufficient funding from the sale of our common stock or through director loans to meet our funding needs after the next nine months.~~

~~The~~Liquidity Independent Auditor's Report to our audited financial statements for the period ended September 30, 2009 indicated that there are a number of factors that raise substantial doubt about our ability to continue as a going concern. Such factors identified in the report include that we need to generate profitable operations and ~~are~~Capital inResources ~~need of obtaining adequate financing. For these and other related reasons our auditors believe that there is substantial doubt that we will be able to continue as a going concern.~~

~~Comparison~~Our cash reserves of ~~Interim~~$26,556 ~~Financial~~as ~~Results~~at March 31, 2010 ($8,573 as at September 30, 2009) are not sufficient to meet our funding needs beyond the next nine-month period. To this effect, the Company will need to seek additional funding in the near future. We currently do not have a specific plan for obtaining such funding, however, we anticipate that any additional funding will be in the form of equity financing from the sale of our common stock and/or loans (interest or convertible). We currently do not have any arrangements in place for any future equity financing. We may also seek to obtain short-term loans from our directors, although no such arrangements have as yet been made. There can be no assurance that we will be able to raise sufficient funding from the sale of our common stock or through director loans to meet our funding needs after the next nine months.

AsThe atIndependent ~~December~~Auditor's 31Report to our audited financial statements for the period ended September 30, 2009, ~~accounts~~indicated ~~payable~~that ~~balance~~there isare ~~$24,507~~a ~~compared~~number of factors that raise substantial doubt about our ability to ~~$30,771~~continue as a atgoing ~~September~~concern. ~~30,~~Such ~~2009~~factors identified in the report include that we need to generate profitable operations and are in need of obtaining adequate financing. For ~~Loan~~these ~~payable~~and ~~balance~~other related reasons our auditors believe that there is ~~$43,431~~substantial ~~compared~~doubt that we will be able to ~~$59,314~~continue as ata ~~September~~going ~~30, 2009~~concern.

~~Sales~~Comparison ~~have~~of ~~decreased~~Interim ~~year~~Financial ~~over year due to the increasing and volatility prices of maize.~~Results

~~Off-Balance~~As ~~Sheet~~at ~~Arrangements~~March 31, 2010, we had an accounts payable balance of $39,444 compared to $30,771 as at September 30, 2009. We did not have a loan payable balance as at March 31, 2010 compared to $59,314 as at September 30, 2009.

~~The~~Sales ~~Company does not~~ have ~~any~~ceased ~~off-balance~~year ~~sheet~~over ~~arrangements that~~year ~~have~~due ~~or are reasonably likely~~ to ~~have a current or future effect on~~ the ~~small~~ ~~business~~increasing ~~issuer's financial condition, changes in financial condition,~~and ~~revenues~~volatility orprices ~~expenses, results~~ of ~~operations, liquidity, capital expenditures or capital resources that is material to investors~~maize.

~~Item~~Off-Balance 3.Sheet ~~Quantitative and Qualitative Disclosures About Market Risk.~~Arrangements

~~Not~~The ~~applicable~~Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the small business issuer's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. The Company's Management under the supervision and with the participation of the Principal Executive Officer and the Principal Financial Officer are responsible for establishing and maintaining "disclosure controls and procedures" (as defined in the Exchange Act) for the Company. Based on their evaluation of the Company's disclosure controls and procedures as of ~~December~~March 31, ~~2009~~2010, the Company's Management has concluded that the Company's disclosure controls and ~~procedures~~ procedures were effective to ensure that the information required to be disclosed by the Company under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the Exchange Act and accumulated and communicated to the Company's Management, including the Principal Executive Officer and the Principal Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. During the fiscal quarter ending ~~December~~March 31, ~~2009~~2010, there were no changes in the Company's internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Limitations on the Effectiveness of Controls. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and the Principal Executive Officer and the Principal Financial Officer have concluded that these controls and procedures are effective at the "reasonable assurance" level.

Item 4T. Controls and Procedures.

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that:

Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the director; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and Exchange Act of 1934, Management assessed the effectiveness of the Company’s internal control over financial reporting as of ~~December~~March 31, ~~2009~~2010. Based on this assessment, the Company's management has concluded that the Company maintained effective internal control over financial reporting as of ~~December~~March 31, ~~2009~~2010, the end of the period covered by this quarterly report.

This quarterly report does not include an attestation report of the company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission ("SEC") that permit the Company to provide only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting. Management has evaluated whether any changes in our internal control over financial reporting that occurred during our last fiscal quarter have materially effected, or reasonably likely to materially effect our internal control over financial reporting. Based on the evaluation we conducted, management has concluded that during the fiscal quarter ending ~~December~~March 31, ~~2009~~2010, there were no changes in the Company's internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and the Principal Executive Officer and the Principal Financial Officer have concluded that these controls and procedures are effective at the "reasonable assurance" level.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any legal proceedings.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

No matters have been submitted to our security holders for a vote, through the solicitation of proxies or otherwise, during the quarterly period ended ~~December~~March 31, ~~2009~~2010.

Item 5. Other Information.

None.

Item 6. Exhibits.

31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~SIGNATURES

		PURE PHARMACEUTICALS CORPORATION
		(Registrant)
Date: February 12, 2010		By: /s/ Roger Gordon
		Roger Gordon
		President, Principal Executive Officer and Director
Date: February 12, 2010		By: /s/ Charlie Lee
		Charlie Lee
		Secretary and Principal Accounting Officer

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PURE PHARMACEUTICALS CORPORATION
		(Registrant)


Date: May 18, 2010		By: /s/ Roger Gordon
		Roger Gordon
		President, Principal Executive Officer and Director



Date: May 18, 2010		By: /s/ Charlie Lee
		Charlie Lee
		Secretary and Principal Accounting Officer

Filing Compare · Pure Minerals, Inc.